Milan Puskar

Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland.

Bausch Health Americas, Inc. manufactures and distributes pharmaceutical products. The company was founded on November 29, 2011 and is headquartered in Bridgewater, NJ.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Centra Financial Holdings, Inc. operated as a bank holding company. The company was founded in October 25, 1999 and was headquartered in Morgantown, WV.

SRKP 5, Inc. was incorporated in the State of Delaware on May 24, 2005. Since inception, the company has been engaged in organizational efforts and obtaining initial financing. The firm was formed as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. The firm, based on proposed business activities, is a 'blank check' company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business.

Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA.

Protea Biosciences, Inc. develops technology for micro fluidic protein separation and detection. The firm develops new technology for the identification, characterization, and quantization of biologically-important molecules for basic research, pharmaceutical development, and diagnostic applications. the company was founded by Steve Turner in 2001 and is headquartered in Morgantown, WV.

Mylan Pharmaceuticals, Inc. develops and manufactures generic prescription products. Its product includes tablets, Fosamax, Sectral, Xanax, capsules, liquids, and transdermal patches. The company was founded in 1961 and is headquartered in Morgantown, WV.

The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012.